Molecular Partners plans to advance MP0726 towards first-in-human imaging in the second half of 2026. The company also provided an update on MP0712, noting that patient dosing is ongoing in the first cohort of a US multicenter Phase 1/2a study, with initial data expected within the next few months and a more comprehensive dataset on safety and efficacy expected in 2027. Additionally, Molecular Partners intends to file two INDs for targeted cancer therapeutics in 2027 and nominate a new RDT target in the second half of 2026. As of March 31, 2026, the company held CHF 79 million in cash and cash equivalents, which it believes will fund operations into late 2027.
Molecular Partners AGMP0726 advancing to first human imaging in H2 2026 and MP0712 Phase 1/2a data expected soon, plus two IND filings planned for 2027.